Home Magazines Editors-in-Chief FAQs Contact Us

PD-L1 expression in Congolese women with triplenegative breast cancer

Journal of Cancer Prevention & Current Research
Stanislas Maseb’a Mwang Sulu,1 Bienvenu Lebwaze Massamba,1-3 Arnold Maseb Sul Sulu,1 Olivier Mukuku,4 Donatien Babaka Batalansi,1,5 Justin Esimo Mboloko,2 Stanislas Okitotsho Wembonyama,6 Antoine Tshimpi Wola,2,7


Introduction: Inhibition of antibody interaction against Programmed Death-Ligand 1 (PD-L1) is becoming a valuable therapeutic strategy in the management of breast cancer (BC). The expression of PD-L1 in Congolese patients with metastatic triple-negative breast cancer (TNBC) has never been reported.
Methods: We investigated PD-L1 expression in a series of Congolese patients diagnosed with TNBC. Immunohistochemical analyzes were performed using anti-PD-L1 antibodies.
Results: In this study, the expression of PD-L1 in samples of patients with TNBC in Kinshasa (Democratic Republic of the Congo) was evaluated. Appropriate tissue samples were available from 14 patients with TNBC. Tumor sections incorporated in paraffin were stained with the PD-L1 antibody. The PD-L1 positive expression rate in TNBC was 71.43% (10/14).
Conclusion: This study quantified the expression of PD-L1 in TNBC for the first time in a Congolese cohort. This opens the possibility of explor


breast cancer, triple-negative, PD-L1, immunohistochemistry, Kinshasa